Gossamer

georgeclerk Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH). The firm has a $9 price target (~984% upside based on June 24 close). Analyst Andreas Argyrides said that the candidate’s safety and efficacy profile makes it “aContinue Reading